Literature DB >> 18042441

A single centre experience of liver disease in adults with cystic fibrosis 1995-2006.

K L Nash1, M E Allison, D McKeon, D J Lomas, C S Haworth, D Bilton, Graeme J M Alexander.   

Abstract

BACKGROUND: Liver disease is an important cause of death in adults with cystic fibrosis (CF). Ursodeoxycholic acid (UDCA) may slow progression. Managing varices and timely evaluation for liver transplantation are important.
METHODS: Adults with CF underwent annual review. Abnormalities of liver function tests or ultrasound prompted referral to the CF/liver clinic where UDCA was commenced. Endoscopic surveillance for varices was undertaken if ultrasound suggested portal hypertension.
RESULTS: 154 patients were followed for a median 5 years. 43 had significant liver disease, 29 had cirrhosis with portal hypertension and 14 had ultrasound evidence of cirrhosis without portal hypertension. All started UDCA. Only one patient developed chronic liver failure and none required liver transplantation. 27 underwent endoscopy; 1 required variceal banding, the others had insignificant varices. Ultrasound was normal in 97 patients while five had steatosis; nine further patients had splenomegaly but no other evidence of portal hypertension. Neither spleen size nor platelet count correlated with portal hypertension.
CONCLUSIONS: Liver disease was common in adults with CF but disease progression was rare. Thus liver disease detected and closely monitored in adults appeared to have a milder course than childhood CF. Splenomegaly, unrelated to portal hypertension may be a consequence of CF.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18042441     DOI: 10.1016/j.jcf.2007.10.004

Source DB:  PubMed          Journal:  J Cyst Fibros        ISSN: 1569-1993            Impact factor:   5.482


  14 in total

1.  Routine OGTT screening for CFRD - no thanks.

Authors:  Martin Walshaw
Journal:  J R Soc Med       Date:  2009-07       Impact factor: 5.344

2.  Adult-onset cystic fibrosis liver disease: Diagnosis and characterization of an underappreciated entity.

Authors:  Christopher Koh; Sasan Sakiani; Pallavi Surana; Xiongce Zhao; Jason Eccleston; David E Kleiner; David Herion; T Jake Liang; Jay H Hoofnagle; Milica Chernick; Theo Heller
Journal:  Hepatology       Date:  2017-06-26       Impact factor: 17.425

3.  Liver: Benefit of liver transplantation in patients with cystic fibrosis.

Authors:  Bruno Gridelli
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-03-08       Impact factor: 46.802

Review 4.  Cystic fibrosis liver disease: A condition in need of structured transition and continuity of care.

Authors:  Julian Hercun; Fernando Alvarez; Catherine Vincent; Marc Bilodeau
Journal:  Can Liver J       Date:  2019-08-27

5.  Incidence and clinical significance of elevated liver function tests in cystic fibrosis clinical trials.

Authors:  Nicole Mayer-Hamblett; Margaret Kloster; Bonnie W Ramsey; Michael R Narkewicz; Lisa Saiman; Christopher H Goss
Journal:  Contemp Clin Trials       Date:  2012-11-29       Impact factor: 2.226

6.  Cholic acid induces a Cftr dependent biliary secretion and liver growth response in mice.

Authors:  Frank A J A Bodewes; Marcel J Bijvelds; Willemien de Vries; Juul F W Baller; Annette S H Gouw; Hugo R de Jonge; Henkjan J Verkade
Journal:  PLoS One       Date:  2015-02-13       Impact factor: 3.240

7.  Hypersplenism in liver disease and SLE revisited: current evidence supports an active rather than passive process.

Authors:  John M Gemery; Andrew R Forauer; Anne M Silas; Eric K Hoffer
Journal:  BMC Hematol       Date:  2016-02-09

Review 8.  Molecular mechanisms of ursodeoxycholic acid toxicity & side effects: ursodeoxycholic acid freezes regeneration & induces hibernation mode.

Authors:  Magd A Kotb
Journal:  Int J Mol Sci       Date:  2012-07-17       Impact factor: 6.208

9.  Non-invasive evaluation of cystic fibrosis related liver disease in adults with ARFI, transient elastography and different fibrosis scores.

Authors:  Thomas Karlas; Marie Neuschulz; Annett Oltmanns; Andrea Güttler; David Petroff; Hubert Wirtz; Jochen G Mainz; Joachim Mössner; Thomas Berg; Michael Tröltzsch; Volker Keim; Johannes Wiegand
Journal:  PLoS One       Date:  2012-07-25       Impact factor: 3.240

10.  Relevance of 3D Cholangiography and Transient Elastography to Assess Cystic Fibrosis-Associated Liver Disease?

Authors:  C Lemaitre; S Dominique; E Billoud; M Eliezer; H Montialoux; M Quillard; G Riachi; E Koning; H Morisse-Pradier; G Savoye; C Savoye-Collet; O Goria
Journal:  Can Respir J       Date:  2016-06-26       Impact factor: 2.409

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.